Stephen Bazeley, MD
Family Medicine · Waterville, OHNPI 1336143049
Payments from drug & device makers
Across 72 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$208
- Pfizer$120
- Novo Nordisk$110
- Boehringer Ingelheim$89
- Amarin Pharma, Inc.$72
- Amgen$48
- plus $504 from 22 others
What the payments were for
- Food & beverage$1,151100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 11 | $208 |
| Pfizer | 8 | $120 |
| Novo Nordisk | 8 | $110 |
| Boehringer Ingelheim | 5 | $89 |
| Amarin Pharma, Inc. | 4 | $72 |
| Amgen | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Lilly USA, LLC | 3 | $41 |
| GSK | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Astellas Pharma US Inc | 2 | $32 |
| Merck | 2 | $31 |
| Johnson & Johnson | 2 | $27 |
| UCB, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $20 |
| Bayer | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Bausch Health US, LLC | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Glenmark Therapeutics Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Corium, LLC | 1 | $12 |
| AstraZeneca | 1 | $11 |
How this compares
$1,151 in reported general payments places this provider in the 65th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 336 | $165,795 |
| JanuviaSitagliptin Phosphate | 205 | $120,732 |
| JardianceEmpagliflozin | 64 | $69,252 |
| Dupixent SyringeDupilumab | 12 | $48,245 |
| MyrbetriqMirabegron | 181 | $43,539 |
| XareltoRivaroxaban | 50 | $36,094 |
| ProliaDenosumab | 14 | $26,147 |
| MounjaroTirzepatide | 17 | $23,719 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $20,557 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $17,536 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $15,800 |
| EntrestoSacubitril/Valsartan | 27 | $15,538 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $12,718 |
| Xtampza ErOxycodone Myristate | 11 | $12,654 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $12,261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $120 | $165,795336 claims |
| MerckJanuvia | $31 | $120,732205 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $89 | $85,05278 claims |
| Astellas Pharma US IncMyrbetriq | $32 | $43,539181 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $33 | $38,09355 claims |
| Johnson & JohnsonXarelto | $27 | $36,09450 claims |
| AmgenProlia | $48 | $26,14714 claims |
| Lilly USA, LLCMounjaro | $41 | $23,71917 claims |
| AbbVieFetzima, Namzaric | $208 | $18,53258 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $16 | $10,83642 claims |
| Sanofi-aventis U.S. LLCMultaq | $43 | $10,27612 claims |
| UCB, Inc.Neupro | $24 | $9,25311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Waterville
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.